Are you Dr. Harmon?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 53 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St Yaw 7
Mass General Hospital
Boston, MA 02114Phone+1 617-726-8748Fax+1 617-726-2894- Is this information wrong?
Summary
- Dr. David Harmon, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is an Assistant Professor at Harvard Medical School.
Education & Training
Harvard Medical SchoolClass of 1974
Certifications & Licensure
MA State Medical License 1979 - 2019
Clinical Trials
- Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall Start of enrollment: 2004 Jun 17
Publications & Presentations
PubMed
- Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.Liao, Y., Chen, L., Feng, Y., Shen, J., Gao, Y., Mankin, H., Duan, Z., Cote, G., Choy, E., Harmon, D., Hornicek, F.> ;Oncotarget. 2024 Feb 5
- Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Liao, Y., Sassi, S., Halvorsen, S., Feng, Y., Shen, J., Gao, Y., Mankin, H., Duan, Z., Cote, G., Choy, E., Harmon, D., Hornicek, F.> ;Scientific Reports. 2024 Jan 22
- 1 citationsAuthor Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Yunfei Liao, Slim Sassi, Stefan Halvorsen, Yong Feng, Jacson Shen, Yan Gao, Gregory M. Cote, Edwin Choy, David C. Harmon, Henry J. Mankin, Francis J. Hornicek, Zhenfen...> ;Scientific Reports. 2018 Aug 9
- Join now to see all
